Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells 15,944 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary Szela sold 15,944 shares of TriSalus Life Sciences stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.85, for a total transaction of $61,384.40. Following the sale, the chief executive officer directly owned 752,987 shares in the company, valued at $2,898,999.95. The trade was a 2.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

TriSalus Life Sciences Price Performance

TLSI stock traded up $0.07 during trading on Friday, reaching $3.93. The company had a trading volume of 396,259 shares, compared to its average volume of 269,887. TriSalus Life Sciences, Inc. has a 52 week low of $3.42 and a 52 week high of $7.95. The business has a 50 day moving average of $4.95 and a 200 day moving average of $5.30.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01. The firm had revenue of $13.21 million for the quarter, compared to the consensus estimate of $13.20 million. On average, sell-side analysts forecast that TriSalus Life Sciences, Inc. will post -1.55 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. Canaccord Genuity Group decreased their price target on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $7.00.

Institutional Trading of TriSalus Life Sciences

Several institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC bought a new stake in TriSalus Life Sciences during the 2nd quarter valued at about $10,900,000. AWM Investment Company Inc. purchased a new stake in shares of TriSalus Life Sciences during the second quarter valued at approximately $6,812,000. Vanguard Group Inc. grew its holdings in shares of TriSalus Life Sciences by 42.4% during the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after buying an additional 345,186 shares during the last quarter. Gilder Gagnon Howe & Co. LLC increased its position in shares of TriSalus Life Sciences by 32.1% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after acquiring an additional 265,618 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in TriSalus Life Sciences by 107.4% in the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after acquiring an additional 235,627 shares during the last quarter. 2.58% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: TriSalus reported a slight quarterly earnings beat on March 5 (EPS -$0.12 vs. consensus -$0.13) with revenue roughly in line with expectations — this gives a fundamental rationale for buying interest. MarketBeat TLSI Summary
• Neutral Sentiment: Trading volume was elevated (≈396k shares vs. ~181k average), suggesting the market is actively re-pricing the name; price remains below the 50-day ($4.95) and 200-day ($5.30) moving averages, a neutral-to-cautious technical backdrop.
• Negative Sentiment: CEO Mary T. Szela sold 15,944 shares on March 17 at an average $3.85 (≈$61.4k) and previously sold 4,358 shares on March 11 at $4.13; these transactions reduced her ownership by ~2.07% and ~0.56% respectively — a notable insider reduction. CEO Form 4
• Negative Sentiment: Other officers also reported multiple small sales this week: Richard Marshak (several sales on Mar 11–16). These are modest in dollar terms but collectively add to negative insider-sentiment signals. Marshak Form 4
• Negative Sentiment: Insider sales by Bryan F. Cox (multiple small sales Mar 11–16) and Jodi Devlin (multiple small sales Mar 11–16) were also disclosed, further contributing to the selling narrative. Cox Form 4 Devlin Form 4

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.